Product Description: Gimsilumab (MORAb-022) is a human anti-GM-CSF monoclonal antibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA)[1][2].
Applications: COVID-19-anti-virus
Formula: N/A
References: [1]Criner GJ, et al. Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med. 2022 Jun 1;205(11):1290-1299. /[2]Crotti C, et al. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Des Devel Ther. 2017 Jan 13;11:211-223.
CAS Number: 1648796-29-5
Molecular Weight: N/A
Research Area: Infection; Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: c-Fms;SARS-CoV